Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 27;2(12):1041–1054. doi: 10.1002/acn3.254

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Improved myelination but persistent gliosis following rapamycin treatment. CKO and littermate control animals were treated with rapamycin 3 mg/kg, 5 days per week from P30 to P60. P60 sagittal brain sections were stained with MBP to identify myelin and GFAP to identify astroctyes (A, B) (cc – corpus callosum, ac – anterior commissure) Scale bar = 100 μm. Gliosis was increased as identified GFAP and s100β expression (C, E, and F) and remained significantly elevated despite rapamycin treatment (D). Expression of MAG improved with rapamycin treatment but did not completely normalize (C, G–I). Data represent mean ± SEM, n = 4 animals per group. *P < 0.05 by one‐way ANOVA followed by Tukey's multiple comparison test. CKO, conditional knockout; MBP, myelin basic protein; GFAP, glial fibrillary acidic protein; MAG, myelin‐associated glycoprotein; ANOVA, analysis of variance.